Zoster vaccines GRADE assessments

GRADE assessment of zoster vaccines 

GRADE assessment of recombinant herpes zoster vaccine (Shingrix) in:

• immunocompetent older adults compared to placebo
• immunocompetent older adults compared to zoster live vaccine (Zostavax) 
• immunocompromised older adults compared to placebo or unvaccinated

ATAGI recommendations 

• Use of Shingrix versus Zostavax in immunocompetent adults aged ≥50 years
• Use of Shingrix in immunocompromised adults aged ≥18 years
• Use of Shingrix in immunocompetent adults aged ≥50 years

Note
These GRADE documents should be read as a supplement to the Australian Immunisation Handbook (Handbook) recommendations.

View the Zoster disease chapter in the Handbook here
View the ATAGI statement on the clinical use of zoster vaccine in older adults in Australia here